Omthera Pharmaceuticals (OMTH) Announces Quarterly Results

Omthera Pharmaceuticals (NASDAQ: OMTH) released its earnings data on Tuesday. The company reported ($3.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($2.31) by $0.77, Analyst Ratings Network reports.

A number of research firms have also recently commented on OMTH. Analysts at Stifel Nicolaus initiated coverage on shares of Omthera Pharmaceuticals in a research note to investors on Tuesday, May 7th. They set a “buy” rating and a $14.00 price target on the stock. On a related note, analysts at Leerink Swann initiated coverage on shares of Omthera Pharmaceuticals in a research note to investors on Tuesday, May 7th. They set an “outperform” rating on the stock. Finally, analysts at Piper Jaffray initiated coverage on shares of Omthera Pharmaceuticals in a research note to investors on Tuesday, May 7th. They set an “overweight” rating on the stock.

Five investment analysts have rated the stock with a buy rating, Omthera Pharmaceuticals has a consensus rating of “Buy” and an average target price of $12.67.

Omthera Pharmaceuticals (NASDAQ: OMTH) traded up 96.60% on Tuesday, hitting $13.31. Omthera Pharmaceuticals has a 52-week low of $5.78 and a 52-week high of $7.80. The stock’s 50-day moving average is currently $7.29. The company’s market cap is $325.0 million.

Omthera Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease.

Latest News

Cohen & Steers Inc. Has $202.73 Million Stake in Kinder Morgan Inc
Cohen & Steers Inc. Has $202.73 Million Stake in Kinder Morgan Inc
Cohen & Steers Inc. Acquires 2,326,047 Shares of Brixmor Property Group Inc
Cohen & Steers Inc. Acquires 2,326,047 Shares of Brixmor Property Group Inc
Investment Analysts’ Weekly Ratings Updates for Dollarama
Investment Analysts’ Weekly Ratings Updates for Dollarama
Ecolab  Lowered to Sell at Zacks Investment Research
Ecolab Lowered to Sell at Zacks Investment Research
NorthWestern  Price Target Raised to $67.00 at KeyCorp
NorthWestern Price Target Raised to $67.00 at KeyCorp
Edison International  Downgraded to “Hold” at Zacks Investment Research
Edison International Downgraded to “Hold” at Zacks Investment Research


© 2006-2018 Ticker Report